drugset / Trial / NCT06507891
A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of single and multiple oral doses of TQ-A3334 and observe the efficacy of TQ-A3334 in combination with anlotinib capsules in patients with non-small cell lung cancer.
Timeline
- Start
- 2020-07-06
- Primary completion
- 2023-08-25
- Completion
- 2024-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | Oral |
| Subject | TQ-A3334 | Other / unclassified | — | Oral |